



Ref: Bio/Acts/ CS/ SE/ Ltrs- NSE/

Date: August 24, 2015

The National Stock Exchange of India Limited
Exchange Plaza
Bandra – Kurla Complex
Bandra (East)
Mumbai- 400 051

Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

www.biocon.com

"By Email & Courier"

Kind Attn: **Mr. Hari K.**

Dear Sir,

Subject: Seeking clarification on media report titled "USFDA observations not serious, says Biocon" published in Business Standard – August 22, 2015.

This is with reference to BSE mail dated August 24, 2015, seeking clarification on media report titled "USFDA observations not serious, says Biocon" published in Business Standard.

We wish to clarify that USFDA conducts audit at regular intervals. Biocon underwent such inspection in June 2015, wherein a few minor observations in the nature of recommendations were made by the regulatory team. All those have been considered by the company and closed out with the FDA.

None of the USFDA observations were material in nature to have bearing on operation/performance of the Company or price sensitive in nature
Kindly take this intimation on record.

Thanking you.

Yours faithfully,
For Biocon Limited

A handwritten signature in black ink, appearing to read "Siddharth Mittal", is written over a horizontal line.

Siddharth Mittal
Chief Financial Officer

By Email to NSE: cmli@nse.co.in

CC: BSE